Novel molecular classification of colorectal cancer and correlation with survival

Globocan [Internet], 2020. 2020 is an online, for all cancer sites combined. <https://www.uicc.org/news/globocan-2020-new-global-cancer-data#:∼:text=GLOBOCAN>. Álvaro, 2019, Clinical and molecular comparative study of colorectal cancer based on age-of-onset and tumor location: two main criteria for subclassifying colorectal cancer, Int. J. Mol. Sci., 20, 10.3390/ijms20040968 Alwers, 2019, External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP BRAF and KRAS, BMC Cancer, 19, 1, 10.1186/s12885-019-5842-7 Belov, 2011, Cell surface markers in colorectal cancer prognosis, Int. J. Mol. Sci., 12, 78, 10.3390/ijms12010078 Salehi far, S., Soltani, M., Zardast, M., Ghasemian Moghaddam, M.R., 2021. Investigating the factors associated with the level of expression of estrogen and progesterone receptors in patients suffering from colorectal cancer. In: Antwi, S. (Ed.), J Cancer Epidemiol [Internet]. 15, 1–6. <https://www.hindawi.com/journals/jce/2021/4478155/>. Qasim, 2011, Immunohistochemical expression of estrogen and progesterone receptors in human colorectal adenoma and carcinoma using specified automated cellular image analysis system: a clinicopathological study, Oman Med. J. [Internet], 26, 307, 10.5001/omj.2011.78 Hasan R, Bhatt D, Khan S, Khan V, Verma AK, Anees A, et al. Association of Her-2 Expression and Clinicopathological Parameters in Colorectal Carcinoma in Indian Population. Open Access Maced J Med Sci [Internet]. 2018 Dec 22;7(1):6–11. Available from: https://spiroski.migration.publicknowledgeproject.org/index.php/mjms/article/view/oamjms.2019.008. Imaizumi K, Suzuki T, Kojima M, Shimomura M, Sakuyama N, Tsukada Y, et al. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer. Cancer Sci [Internet]. 2020 Jan 18;111(1):23–35. Available from: https://onlinelibrary.wiley.com/doi/10.1111/cas.14223. Tukaram Patil, 2019, Histopathological evaluation and analysis of immunohistochemical expression of bcl-2 oncoprotein in colorectal carcinoma, Iran J Pathol [Internet]., 14, 317, 10.30699/IJP.2019.102982.2028 Kim, 2021, E-cadherin and angiopoietin-2 as potential biomarkers for colorectal cancer with peritoneal carcinomatosis, Anticancer Res [Internet]., 41, 4497, 10.21873/anticanres.15260 Lakpa, 2021, Role of immunohistochemistry markers (p53 and CEA), in study of colorectal tumours, J. Pharm. Res. Int. [Internet], 94, 10.9734/jpri/2021/v33i20B31362 Uhlyarik, 2020, EGFR protein expression of KRAS wild-type colorectal cancer: predictive value of the sidedness for efficacy of anti-EGFR therapy, Pathol Oncol Res [Internet]., 26, 1429, 10.1007/s12253-018-00572-2 Mohamed, S.Y., Mohammed, H.L., Ibrahim, H.M., Mohamed, E.M., Salah, M., 2019. Role of VEGF, CD105, and CD31 in the prognosis of colorectal cancer cases. J. Gastrointest Cancer [Internet] 50(1), 23–34. <https://link.springer.com/10.1007/s12029-017-0014-y>. Pyo J-S, Ko SH, Ko YS, Kim NY. Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression. Pathol - Res Pract [Internet]. 2020 Feb;216(2):152764. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0344033819320047. Aasebø, K., Dragomir, A., Sundström, M., Mezheyeuski, A., Edqvist, P.-H., Eide, G.E., et al., 2020. CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup. Front Oncol [Internet], 10. <https://www.frontiersin.org/article/10.3389/fonc.2020.00008/full>. Al-Maghrabi, J., Emam, E., Gomaa, W., 2018. Immunohistochemical staining of cytokeratin 20 and cytokeratin 7 in colorectal carcinomas: four different immunostaining profiles. Saudi J. Gastroenterol. [Internet] 24(2), 129. <http://www.saudijgastro.com/text.asp?2018/24/2/129/229487>. Howell, 1984, Steroid-hormone receptors and survival after first relapse in breast cancer, Lancet, 323, 588, 10.1016/S0140-6736(84)90995-4 Syed, 2013, Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts, Brit. J. Cancer., 108, 10.1038/bjc.2012.601 Camp, 2004, X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization, Clin. Cancer Res., 10, 7252, 10.1158/1078-0432.CCR-04-0713 Perea, J., Rueda, D., Canal, A., Rodríguez, Y., Álvaro, E., Osorio, I., et al., 2014. Age at onset should be a major criterion for subclassification of colorectal cancer. J. Mol. Diagnos. [Internet] 16(1), 116–26. <http://dx.doi.org/10.1016/j.jmoldx.2013.07.010>. Perez Villamil, B., Romera Lopez, A., Hernandez Prieto, S., Lopez Campos, G., Calles, A., Lopez Asenjo, J.A., et al., 2012. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behaviour, BMC Cancer [Internet] 12(1), 1. Available from: BMC Cancer. Alwers, E., Jia, M., Kloor, M., Bläker, H., Brenner, H., Hoffmeister, M., 2019. Associations between molecular classifications of colorectal cancer and patient survival: a systematic review, Clin. Gastroenterol. Hepatol. [Internet] 17(3), 402–410.e2. doi:10.1016/j.cgh.2017.12.038. Trinh, 2017, Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry, Clin. Cancer Res., 23, 387, 10.1158/1078-0432.CCR-16-0680 Stintzing, 2019, Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial, Ann. Oncol., 30, 1796, 10.1093/annonc/mdz387 Phipps, 2015, Association between molecular subtypes of colorectal cancer and patient survival, Gastroenterology, 148, 77, 10.1053/j.gastro.2014.09.038 Purcell, 2019, Molecular subtyping improves prognostication of Stage 2 colorectal cancer, BMC Cancer., 19, 1, 10.1186/s12885-019-6327-4 Nasierowska-Guttmejer, 2000, P53 protein accumulation and P53 gene mutation in colorectal cancer, Pathol. Oncol. Res., 6, 275, 10.1007/BF03187331 Konda, 2014, Distinct molecular features of different macroscopic subtypes of colorectal neoplasms, PLoS One., 9, 10.1371/journal.pone.0103822 Xu, 2007, Classification based on the combination of molecular and pathologic predictors is superior to molecular classification on prognosis in colorectal carcinoma, Clin. Cancer Res., 13, 5082, 10.1158/1078-0432.CCR-07-0597 Sugai, 2017, Molecular subtypes of colorectal cancers determined by PCR-based analysis, Cancer Sci., 108, 427, 10.1111/cas.13164 Domingo, 2013, Use of multivariate analysis to suggest a new molecular classification of colorectal cancer, J. Pathol., 229, 441, 10.1002/path.4139 Osako, 1998, Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival, Oncology., 55, 548, 10.1159/000011911 Azcue, 2021, Pd-l1 as a prognostic factor in early-stage colon carcinoma within the immunohistochemical molecular subtype classification, Cancers (Basel)., 13, 1, 10.3390/cancers13081943 Shiovitz, 2015, Molecular markers predictive of chemotherapy response in colorectal cancer, Curr. Gastroenterol. Rep., 17, 1, 10.1007/s11894-015-0431-7